BMS/AstraZeneca seek 2nd chance at FDA for dapagliflozin
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and AstraZeneca are seeking a second chance at the US FDA for their earlier rejected type 2 diabetes drug dapagliflozin.